SAN FRANCISCO, November 03, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy ...

Ohio University’s Honors Tutorial College (HTC) is now accepting applications for two Faculty Fellow positions and for the Faculty Fellow for Wellness position. Applications for these positions are ...

Photoshop CS5 tutorial showing how to create a planetary eclipse in deep space and customized, 3D text. Subscribe! Comedian’s arrest over social media posts sparks warning for Americans More than a ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

In March, observers in Chile were treated to an especially spectacular sight, as the night sky lit up with orange and green hues. To top it off, the moon was in a full lunar eclipse. The two ...

This virtual summit will bring together education leaders, policymakers, and industry experts to explore the critical steps involved in developing, funding, and scaling successful, state and ...

PROGRAM LAUNCH. Over 400 participants attend the Tara, Basa! Tutoring Program (TBTP) launch in Butuan City and Siargao Island, Surigao del Norte, on March 18, 2025. The DSWD-led initiative aims to ...

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is ...